Actively Recruiting
Randomized Study of ALN-ANG3 to Evaluate Safety, Effectiveness, and Drug Effects in Adults with Diabetic Kidney Disease
Led by Regeneron Pharmaceuticals · Updated on 2026-10-27
195
Participants Needed
59
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying an experimental drug called ALN-ANG3 in adults with diabetic kidney disease to evaluate its safety and effectiveness. The study also explores side effects and how the drug behaves in the blood over time. This research is a Phase 2 randomized, double-blind, placebo-controlled trial sponsored by Regeneron Pharmaceuticals. Participants receive different treatments including ALN-ANG3 alone, ALN-ANG3 combined with evinacumab which is no longer administered, or a placebo. Treatments are given according to the study protocol. The study monitors participants over 24 weeks for changes in kidney function, cholesterol levels, and drug concentrations, with safety followed up to 48 weeks. During the study, participants undergo regular evaluations including urine and blood tests to measure kidney function and cholesterol. Researchers track side effects and immune responses to the drug. The main outcome is the change in urine albumin to creatinine ratio after 24 weeks. The study lasts up to about 48 weeks including safety monitoring and aims to provide important information about ALN-ANG3 in diabetic kidney disease.
CONDITIONS
Brief Title
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here